Physician profile
Dmitry Khasak
NPI 1649258286
$18,789.56
in general payments reported to CMS, 2019-2025
38 companies · $2,297 in 2025
The $2,297 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,267 · 2020: $2,010 · 2021: $1,399 · 2022: $2,967 · 2023: $4,094 · 2024: $3,755 · 2025: $2,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,787 · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,787.10 |
| Education | $358.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $3,055.59 | 2022-2024 | Vtama |
| Abbvie INC. | $2,237.13 | 2019-2025 | |
| Janssen Biotech, INC. | $1,918.03 | 2019-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $1,170.84 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $1,108.93 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,077.16 | 2019-2021 | |
| Amgen INC. | $957.26 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $831.57 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $785.13 | 2022-2025 | Sotyktu |
| Incyte Corporation | $781.30 | 2021-2025 | Opzelura |
| Almirall LLC | $671.23 | 2020-2025 | Seysara, Klisyri |
| Genzyme Corporation | $590.68 | 2019-2025 | |
| Galderma Laboratories, L.P. | $588.41 | 2019-2024 | Aklief, Oracea, Epsolay |
| Pfizer INC. | $581.72 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $285.04 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $283.46 | 2021-2024 | |
| Ucb, INC. | $265.27 | 2021-2025 | Bimzelx, Cimzia |
| Smith+Nephew, INC. | $253.38 | 2020-2025 | Collagenase Santyl, Regranex |
| Organon LLC | $206.57 | 2025 | Vtama |
| Leo Pharma INC. | $148.82 | 2019-2025 | Anzupgo |
| Lilly USA, LLC | $142.42 | 2019-2022 | |
| Epi Health, LLC | $132.20 | 2020-2022 | |
| Vyne Pharmaceuticals INC. | $112.43 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $107.41 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $104.65 | 2023 | Uzedy |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Botanix Sb INC | $41.18 | 2025 | Sofdra |
| Phadia US INC. | $39.25 | 2021-2022 | |
| Melinta Therapeutics, LLC | $38.10 | 2019 | |
| Cipher Pharmaceuticals US LLC | $34.64 | 2025 | Spinosad, Natroba |
| Celgene Corporation | $27.94 | 2019 | |
| Exact Sciences Corporation | $25.03 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.66 | 2023 | Cyltezo |
| Shield Therapeutics INC | $18.97 | 2025 | |
| Genentech USA, INC. | $18.61 | 2019 | |
| Encore Dermatology INC. | $17.69 | 2020 | |
| Medimetriks Pharmaceuticals, INC. | $15.56 | 2019 | |
| Promius Pharma LLC | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Khasak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.